High-density lipoproteins neutralize C-reactive protein proinflammatory activity
C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This fac...
Saved in:
Published in | Circulation (New York, N.Y.) Vol. 109; no. 17; pp. 2116 - 2122 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hagerstown, MD
Lippincott Williams & Wilkins
04.05.2004
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified. Method and Results- The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine was the fundamental active component.
The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components. |
---|---|
AbstractList | BACKGROUNDC-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified. Method and Results- The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine was the fundamental active component.CONCLUSIONSThe CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components. C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified. Method and Results- The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine was the fundamental active component. The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components. Background— C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive expression of low levels of CRP in normal plasma suggests the likelihood that a natural factor exists to neutralize the effect of CRP. This factor(s) has not yet been identified. Method and Results— The proinflammatory effect of CRP was measured by the induction of inflammatory adhesion molecules in human umbilical vein endothelial cells (HUVECs). We show that CRP significantly induced upregulation of adhesion molecules in both protein and mRNA levels. The CRP-induced expression of these inflammatory adhesion molecules was completely suppressed when the cells were preincubated with a physiological concentration (1 mg/mL apolipoprotein A-I) of HDLs derived from human plasma (native HDL) or reconstituted HDL (rHDL) at a very low concentration (0.01 mg/mL apolipoprotein A-I). A novel mechanism of HDL inhibition is likely to operate, because (1) rHDL was 100 times more potent than native HDL, (2) preincubation with HDL and its sustained presence were obligatory, and (3) oxidized 1-palmitoyl-2-linoleoyl- sn -glycero-3-phosphocholine was the fundamental active component. Conclusions— The CRP-induced upregulation of inflammatory adhesion molecules in HUVECs was completely prevented by HDL via their oxidized phospholipid components. |
Author | BAGLEY, Christopher J GAMBLE, Jennifer R LIJUN WANG RYE, Kerry-Anne PU XIA ALBANESE, Nathaniel ROBERTS, Jane WADHAM, Carol BARTER, Philip J VADAS, Mathew A |
Author_xml | – sequence: 1 givenname: Carol surname: WADHAM fullname: WADHAM, Carol organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia – sequence: 2 givenname: Nathaniel surname: ALBANESE fullname: ALBANESE, Nathaniel organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia – sequence: 3 givenname: Jane surname: ROBERTS fullname: ROBERTS, Jane organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia – sequence: 4 surname: LIJUN WANG fullname: LIJUN WANG organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia – sequence: 5 givenname: Christopher J surname: BAGLEY fullname: BAGLEY, Christopher J organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia – sequence: 6 givenname: Jennifer R surname: GAMBLE fullname: GAMBLE, Jennifer R organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia – sequence: 7 givenname: Kerry-Anne surname: RYE fullname: RYE, Kerry-Anne organization: Lipid Research Group, The Heart Research Institute, Camperdown, NSW, Australia – sequence: 8 givenname: Philip J surname: BARTER fullname: BARTER, Philip J organization: Lipid Research Group, The Heart Research Institute, Camperdown, NSW, Australia – sequence: 9 givenname: Mathew A surname: VADAS fullname: VADAS, Mathew A organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia – sequence: 10 surname: PU XIA fullname: PU XIA organization: Division of Human Immunology, Hanson Institute, Institute of Medical and Veterinary Science, Adelaide, South Australia, Australia |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15835560$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/15078800$$D View this record in MEDLINE/PubMed |
BookMark | eNpNkMlKBDEQQIMoOi6_II2gt26zp-NNBjcQFNFzyKQrGullTHqE8euNY4PWpSjq1cLbR9v90ANCJwRXhEhyjkk1v3uqcA5CFSe64kIrUVG5hWZEUF5ywfQ2mmVAl4pRuof2U3rPpWRK7KI9IrCqa4xn6PE2vL6VDfQpjOuiDcthGYcRQp-KHlZjtG34gmJeRrBuDJ9QTO2fHHrf2q6z4xDXxaaddxyiHW_bBEdTPkAv11fP89vy_uHmbn55XzqB5Vhy0jBPPadacMmVVVovQNhGW-qZchxL8NzKBjjTteLCu5oCk9JZsfBQE3aAzn735kc-VpBG04XkoG1tD8MqGUVqrXCtM3jxC7o4pBTBm2UMnY1rQ7D58WkwMdmn-fNpNj4NlXn4eLqyWnTQ_I1OAjNwOgE2Odv6aHsX0j-uZkJIzL4BtOKBrg |
CODEN | CIRCAZ |
CitedBy_id | crossref_primary_10_1097_00041433_200412000_00005 crossref_primary_10_1289_EHP2062 crossref_primary_10_4049_jimmunol_1001534 crossref_primary_10_1074_jbc_M608175200 crossref_primary_10_1157_13095098 crossref_primary_10_1016_j_metabol_2009_05_004 crossref_primary_10_31857_S0320972521100031 crossref_primary_10_1016_j_coi_2007_11_001 crossref_primary_10_1097_01_hco_0000184529_52832_e6 crossref_primary_10_1002_dmrr_2372 crossref_primary_10_1038_labinvest_2011_42 crossref_primary_10_1007_s00592_009_0150_3 crossref_primary_10_1016_j_cjca_2012_05_003 crossref_primary_10_1055_s_0041_1731273 crossref_primary_10_1194_jlr_M600227_JLR200 crossref_primary_10_1074_jbc_M512538200 crossref_primary_10_1038_oby_2010_114 crossref_primary_10_18699_SSMJ20220605 crossref_primary_10_3390_metabo11120874 crossref_primary_10_1134_S1990750818020075 crossref_primary_10_2147_IJGM_S324889 crossref_primary_10_1155_2022_2993309 crossref_primary_10_1007_s40572_014_0011_2 crossref_primary_10_1586_eci_10_98 crossref_primary_10_1371_journal_pone_0071235 crossref_primary_10_1007_s11745_009_3369_4 crossref_primary_10_1134_S1990519X23040090 crossref_primary_10_1134_S0006297921100047 crossref_primary_10_1089_jir_2019_0029 crossref_primary_10_2217_17460875_1_5_517 crossref_primary_10_1093_toxsci_kft130 crossref_primary_10_1515_cclm_2011_772 crossref_primary_10_1002_art_22201 crossref_primary_10_1016_j_atherosclerosis_2013_08_037 crossref_primary_10_1111_j_1538_7836_2008_03175_x crossref_primary_10_1194_jlr_R400017_JLR200 crossref_primary_10_1038_ncpcardio0074 crossref_primary_10_1002_oby_20332 crossref_primary_10_1016_j_atherosclerosis_2005_10_032 crossref_primary_10_3390_biology11030430 crossref_primary_10_1097_00075197_200503000_00007 crossref_primary_10_1097_01_mol_0000169356_58513_25 crossref_primary_10_1016_j_atherosclerosis_2005_12_026 crossref_primary_10_1080_07853890500526352 crossref_primary_10_1007_s13340_011_0059_2 crossref_primary_10_1016_j_dci_2005_03_009 crossref_primary_10_1002_art_27447 crossref_primary_10_1002_clc_20692 crossref_primary_10_1097_MCI_0b013e32831550d9 crossref_primary_10_1016_j_biopha_2008_12_002 crossref_primary_10_1016_j_atherosclerosissup_2005_02_004 crossref_primary_10_2174_0929867326666190516103953 crossref_primary_10_3389_fendo_2023_1275132 crossref_primary_10_5551_jat_E571 crossref_primary_10_1021_acs_jproteome_5b00419 crossref_primary_10_3390_healthcare10101982 crossref_primary_10_1016_j_cca_2015_10_021 crossref_primary_10_1016_j_plipres_2012_03_003 crossref_primary_10_1007_s10654_017_0251_1 crossref_primary_10_1016_j_metabol_2010_04_018 crossref_primary_10_1016_j_rpth_2023_100063 crossref_primary_10_1016_j_imbio_2011_07_030 crossref_primary_10_1093_intimm_dxl023 crossref_primary_10_1111_j_0894_0959_2004_17604_x crossref_primary_10_1016_j_actbio_2016_02_008 crossref_primary_10_1016_j_clinbiochem_2009_11_018 crossref_primary_10_1194_jlr_M800271_JLR200 crossref_primary_10_2310_JIM_0b013e31824e980c crossref_primary_10_1038_s41598_022_07271_8 crossref_primary_10_1016_j_clinbiochem_2009_01_010 crossref_primary_10_1185_030079905X26216 crossref_primary_10_1111_j_1468_1331_2007_02026_x crossref_primary_10_1007_s00281_009_0149_4 crossref_primary_10_1155_2012_181394 crossref_primary_10_1016_j_freeradbiomed_2017_07_032 crossref_primary_10_1097_HCO_0b013e3283043806 crossref_primary_10_18097_PBMC20186401066 crossref_primary_10_1152_ajpheart_01418_2006 crossref_primary_10_1016_j_ahj_2011_12_017 crossref_primary_10_1093_eurheartj_sui036 crossref_primary_10_1152_ajpheart_00067_2011 crossref_primary_10_1111_j_1440_1681_2009_05338_x crossref_primary_10_1111_j_1365_2567_2006_02516_x crossref_primary_10_1590_S0074_02762011000800014 crossref_primary_10_1016_S1131_3587_05_74096_6 crossref_primary_10_7793_jcoron_20_033 crossref_primary_10_1016_S0214_9168_08_72596_8 crossref_primary_10_1159_000090435 crossref_primary_10_1177_0961203306071668 crossref_primary_10_1007_s12010_011_9270_7 crossref_primary_10_1016_j_atherosclerosis_2009_05_034 crossref_primary_10_1371_journal_pone_0070533 crossref_primary_10_1016_S1131_3587_12_70040_7 crossref_primary_10_1093_eurheartj_sui044 crossref_primary_10_1097_TEN_0b013e3181a6a5ed crossref_primary_10_1586_14779072_2014_896741 crossref_primary_10_1155_2013_186365 crossref_primary_10_2174_1568026620666200427091454 crossref_primary_10_1080_14017430701411234 crossref_primary_10_1016_j_amjmed_2012_02_013 crossref_primary_10_3390_biomedicines8120620 crossref_primary_10_1016_j_cbd_2018_10_001 crossref_primary_10_1016_j_ijcard_2006_11_010 crossref_primary_10_1111_j_1365_2796_2006_01608_x crossref_primary_10_1128_IAI_00359_06 crossref_primary_10_1371_journal_pone_0116867 |
Cites_doi | 10.1161/atvb.18.9.1450 10.1056/NEJM200003233421202 10.1016/S0022-2275(20)33434-9 10.1074/jbc.274.46.33143 10.1084/jem.190.4.585 10.1016/S0021-9150(00)00659-6 10.1161/01.cir.0000033116.22237.f9 10.1046/j.1365-2249.2000.01281.x 10.1016/0076-6879(86)28092-1 10.1038/nature01023 10.1161/01.cir.0000029802.88087.5e 10.1016/S0002-9149(01)01799-4 10.1161/circ.103.21.2531 10.1161/circ.102.18.2165 10.1161/01.CIR.104.2.145 10.1002/jcp.1040960209 10.1161/atvb.15.11.1987 10.1073/pnas.96.21.12010 10.1161/res.88.9.877 10.1016/S0021-9258(18)34756-2 10.1016/0952-7915(95)80029-8 10.1073/pnas.192399699 10.1016/0022-1759(94)90366-2 10.1002/1097-0320(20000701)40:3<238::AID-CYTO9>3.0.CO;2-3 10.4049/jimmunol.150.10.4494 10.1001/jama.285.19.2481 10.1046/j.1365-2249.1998.00597.x |
ContentType | Journal Article |
Copyright | 2004 INIST-CNRS |
Copyright_xml | – notice: 2004 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1161/01.CIR.0000127419.45975.26 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1524-4539 |
EndPage | 2122 |
ExternalDocumentID | 10_1161_01_CIR_0000127419_45975_26 15078800 15835560 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .-D .3C .55 .GJ .XZ .Z2 01R 08R 0R~ 0ZK 18M 1CY 1J1 29B 2FS 2WC 354 40H 41~ 4Q1 4Q2 4Q3 53G 5GY 5RE 5VS 6PF 71W 77Y 7O~ AAAXR AAEJM AAGIX AAHPQ AAJCS AAMOA AAMTA AAPBV AAQKA AARTV AASOK AASXQ AAUGY AAWTL AAXQO AAYOK ABASU ABBUW ABDIG ABOCM ABPMR ABPTK ABQRW ABXVJ ABZAD ACCJW ACDDN ACEWG ACGFO ACGFS ACILI ACOAL ACRKK ACRZS ACWDW ACWRI ACXNZ ADBBV ADCYY ADFPA ADGGA ADNKB AE3 AE6 AEBDS AEETU AENEX AFCHL AFDTB AFFNX AFUWQ AGINI AHMBA AHOMT AHRYX AHVBC AIJEX AJIOK AJJEV AJNWD AJNYG AKALU AKULP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AOHHW ASPBG AVWKF AWKKM AYCSE AZFZN BAWUL BOYCO BQLVK BS7 BYPQX C1A C45 CS3 DIK DIWNM DU5 DUNZO E.X E3Z EBS EEVPB EJD EX3 F2K F2L F2M F2N F5P FCALG FEDTE FL- FW0 GNXGY GQDEL GX1 H0~ H13 HZ~ H~9 IKREB IKYAY IN~ IPNFZ IQODW J5H JF9 JG8 JK3 JK8 K-A K-F K8S KD2 KMI KQ8 L-C L7B M18 MVM N4W N9A NEJ N~7 N~B N~M O9- OAG OAH OBH OCB OCUKA ODA ODMTH OGEVE OHH OHT OHYEH OJAPA OK1 OL1 OLB OLG OLH OLU OLV OLW OLY OLZ OPUJH ORVUJ OUVQU OVD OVDNE OVIDH OVLEI OVOZU OWBYB OWU OWV OWW OWX OWY OWZ OXXIT P-K P2P PQQKQ R58 RAH RHF RIG RLZ S4R S4S T8P TEORI TR2 TSPGW UPT V2I VVN W2D W3M W8F WH7 WHG WOQ WOW X3V X3W X7M XXN XYM YFH YOC YQJ YSK YXB YYM YYP YZZ ZA5 ZFV ZGI ZXP ZY1 ZZMQN ~H1 AAAAV AAIQE AAUEB ABJNI ADHPY AFEXH AHQNM AINUH AJZMW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c506t-41d3f2f42954647a799be5ad9a2f37c406ef4a6de4398745fc82e366ca5bfe813 |
ISSN | 0009-7322 |
IngestDate | Fri Oct 25 06:04:49 EDT 2024 Fri Aug 23 01:12:42 EDT 2024 Tue Oct 15 23:27:43 EDT 2024 Sun Oct 22 16:06:03 EDT 2023 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 17 |
Keywords | Vascular disease Atherosclerosis protein Cardiovascular disease Inflammation Lipoprotein C reactive protein lipoproteins |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c506t-41d3f2f42954647a799be5ad9a2f37c406ef4a6de4398745fc82e366ca5bfe813 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.ahajournals.org/doi/pdf/10.1161/01.CIR.0000127419.45975.26 |
PMID | 15078800 |
PQID | 71897089 |
PQPubID | 23479 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_71897089 crossref_primary_10_1161_01_CIR_0000127419_45975_26 pubmed_primary_15078800 pascalfrancis_primary_15835560 |
PublicationCentury | 2000 |
PublicationDate | 2004-05-04 |
PublicationDateYYYYMMDD | 2004-05-04 |
PublicationDate_xml | – month: 05 year: 2004 text: 2004-05-04 day: 04 |
PublicationDecade | 2000 |
PublicationPlace | Hagerstown, MD |
PublicationPlace_xml | – name: Hagerstown, MD – name: United States |
PublicationTitle | Circulation (New York, N.Y.) |
PublicationTitleAlternate | Circulation |
PublicationYear | 2004 |
Publisher | Lippincott Williams & Wilkins |
Publisher_xml | – name: Lippincott Williams & Wilkins |
References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_18_2 e_1_3_3_13_2 e_1_3_3_12_2 e_1_3_3_15_2 e_1_3_3_14_2 e_1_3_3_11_2 e_1_3_3_10_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_24_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_25_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_1_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_3_2 e_1_3_3_21_2 |
References_xml | – ident: e_1_3_3_13_2 doi: 10.1161/atvb.18.9.1450 – ident: e_1_3_3_8_2 doi: 10.1056/NEJM200003233421202 – ident: e_1_3_3_17_2 doi: 10.1016/S0022-2275(20)33434-9 – ident: e_1_3_3_19_2 doi: 10.1074/jbc.274.46.33143 – ident: e_1_3_3_23_2 doi: 10.1084/jem.190.4.585 – ident: e_1_3_3_18_2 doi: 10.1016/S0021-9150(00)00659-6 – ident: e_1_3_3_3_2 doi: 10.1161/01.cir.0000033116.22237.f9 – ident: e_1_3_3_25_2 doi: 10.1046/j.1365-2249.2000.01281.x – ident: e_1_3_3_15_2 doi: 10.1016/0076-6879(86)28092-1 – ident: e_1_3_3_22_2 doi: 10.1038/nature01023 – ident: e_1_3_3_2_2 doi: 10.1161/01.cir.0000029802.88087.5e – ident: e_1_3_3_27_2 doi: 10.1016/S0002-9149(01)01799-4 – ident: e_1_3_3_1_2 doi: 10.1161/circ.103.21.2531 – ident: e_1_3_3_4_2 doi: 10.1161/circ.102.18.2165 – ident: e_1_3_3_26_2 doi: 10.1161/01.CIR.104.2.145 – ident: e_1_3_3_10_2 doi: 10.1002/jcp.1040960209 – ident: e_1_3_3_7_2 doi: 10.1161/atvb.15.11.1987 – ident: e_1_3_3_21_2 doi: 10.1073/pnas.96.21.12010 – ident: e_1_3_3_6_2 doi: 10.1161/res.88.9.877 – ident: e_1_3_3_14_2 doi: 10.1016/S0021-9258(18)34756-2 – ident: e_1_3_3_5_2 doi: 10.1016/0952-7915(95)80029-8 – ident: e_1_3_3_20_2 doi: 10.1073/pnas.192399699 – ident: e_1_3_3_16_2 doi: 10.1016/0022-1759(94)90366-2 – ident: e_1_3_3_12_2 doi: 10.1002/1097-0320(20000701)40:3<238::AID-CYTO9>3.0.CO;2-3 – ident: e_1_3_3_11_2 doi: 10.4049/jimmunol.150.10.4494 – ident: e_1_3_3_9_2 doi: 10.1001/jama.285.19.2481 – ident: e_1_3_3_24_2 doi: 10.1046/j.1365-2249.1998.00597.x |
SSID | ssj0006375 |
Score | 2.22068 |
Snippet | C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The constitutive... Background— C-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The... BACKGROUNDC-reactive protein (CRP), a well-recognized marker of atherosclerosis, has recently been suggested to have a direct proinflammatory effect. The... |
SourceID | proquest crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 2116 |
SubjectTerms | Animals Aorta Biological and medical sciences Blood and lymphatic vessels C-Reactive Protein - antagonists & inhibitors C-Reactive Protein - pharmacology Cardiology. Vascular system Cattle Cell Adhesion Cells, Cultured - drug effects Cells, Cultured - metabolism Culture Media, Conditioned - pharmacology Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous E-Selectin - biosynthesis E-Selectin - genetics Endothelial Cells - drug effects Endothelial Cells - metabolism Gene Expression Regulation - drug effects Humans Inflammation Intercellular Adhesion Molecule-1 - biosynthesis Intercellular Adhesion Molecule-1 - genetics Lipoproteins, HDL - pharmacology Liposomes - pharmacology Medical sciences Oxidation-Reduction Phosphatidylcholines - pharmacology Recombinant Proteins - pharmacology RNA, Messenger - biosynthesis RNA, Messenger - genetics U937 Cells - drug effects Umbilical Veins Vascular Cell Adhesion Molecule-1 - biosynthesis Vascular Cell Adhesion Molecule-1 - genetics |
Title | High-density lipoproteins neutralize C-reactive protein proinflammatory activity |
URI | https://www.ncbi.nlm.nih.gov/pubmed/15078800 https://search.proquest.com/docview/71897089 |
Volume | 109 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swEBdZB2MwytZuXfbR-WHsJSizLVmyHt0sI-mabKQJ7ZvxhwSGNQmt89D-Ufsbd5Id2yku-3hxgoUtrPvpdLr76Q6hjwQWNUBOjO3EFZimtoeFLRnmcaRil4OFZPIWTKZstKCnl95lp_OrwVra5HE_uWs9V_I_UoV7IFd9SvYfJFu9FG7Af5AvXEHCcP0rGWuSBk41BV3Xf8jWK5N1QZNelnJjXBh3sjfAYBcardYrm_UvdA9YuCpi7KY5y3civIPsOilLe7VV7Gl4EC6CL6Ng0mSPFBA6Owmmw_NhocO1hz6TVePs-8lwNj8veLp1ZP9sfLqY9i6CMsvV1htBDfev9ka2ZZUw3ojsp6b87GhigTkpziT3Zal8XYqpVyQ3qrSzLZow5DvK1mGNhRsWYbd9UWCOOejQH4xnJl-lo3P2iD6FzZTXd1sycd9bISveouOBwQo24iP02AXFZmgB42_Vys8I97aV-_S3lUluof_PD_e-YxA9W0c3MDdVUVTl4V2PsX7mz9F-uW2xggKDL1BHLg_QYbAE_FzdWp8sQyQ2EZoD9GRS8jUO0Y8mQq0mQq0aoVaNUKtstu4h1Noi9CVafB3OByNc1vDAiWezHFMnJcpVVIeTGeURFyKWXpSKyFWEJ2BOSkUjlkowjHXlBZX4riSMJZEXK-k75BXaW66W8jWyuPIViWRkc8VoYhMRe4mvMyuTiKeUyC4i24EM10WqltBscZkT2k4Iwx_Wwx-a4Q9d1kXHO2NeP1rKuos-bIUQgurV8TSYF6vNTQhmneC2L7roqJBN41mwvGEr9uZPL3-Lntaz6B3ay6838j1YuXl8bKD1GzzroVM |
link.rule.ids | 315,783,787,27936,27937 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=High-density+lipoproteins+neutralize+C-reactive+protein+proinflammatory+activity&rft.jtitle=Circulation+%28New+York%2C+N.Y.%29&rft.au=WADHAM%2C+Carol&rft.au=ALBANESE%2C+Nathaniel&rft.au=ROBERTS%2C+Jane&rft.au=LIJUN+WANG&rft.date=2004-05-04&rft.pub=Lippincott+Williams+%26+Wilkins&rft.issn=0009-7322&rft.eissn=1524-4539&rft.volume=109&rft.issue=17&rft.spage=2116&rft.epage=2122&rft_id=info:doi/10.1161%2F01.CIR.0000127419.45975.26&rft.externalDBID=n%2Fa&rft.externalDocID=15835560 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0009-7322&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0009-7322&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0009-7322&client=summon |